Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice
Metrics: PDF 1010 views | ?
1 Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02129, USA
2 Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
Published: July 13, 2018
This article has been corrected: The correctly spelled author name is given below:
Original article: Oncotarget. 2017; 8:94040-94053. DOI: https://doi.org/10.18632/oncotarget.21541.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.